Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management

Srivastava, Shriyansh; Jayaswal, Nandani; Kumar, Sachin; Sharma, Pramod Kumar; Behl, Tapan; Khalid, Asaad; Mohan, Syam; Najmi, Asim; Zoghebi, Khalid; Alhazmi, Hassan A.

doi:10.1016/j.cellsig.2023.110932

Cited by 19 publications

(6 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improvements in the accuracy and prognostic value of liquid biopsy thanks to AI have been reported in other, nonthoracic malignancies, such as ovarian cancer 38 . Similar investigations are currently underway in lung cancer, analyzing biomarkers which can be drawn from peripheral blood samples to guide diagnosis and individualize treatment recommendations 39,40 …”

Section: Advancements In Screening and Diagnosismentioning

confidence: 88%

What's new in thoracic oncology

Pezeshkian,

McAllister,

Singh

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

Many changes have occurred in the field of thoracic surgery over the last several years. In this review, we will discuss new diagnostic techniques for lung cancer, innovations in surgery, and major updates on latest treatment options including immunotherapy. All these have significantly started to change our approach toward the management of lung cancer and have great potential to improve the lives of our patients afflicted with this disease.

show abstract

Section: Advancements In Screening and Diagnosismentioning

confidence: 88%

What's new in thoracic oncology

Pezeshkian,

McAllister,

Singh

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…As everyone knows,effective criteria can help clinicians to judge the effectiveness of treatment and the risk of recurrence can effectively avoid the occurrence of excessive diagnosis and treatment. For example, risk prognostic signatures can be used to predict the risk of distant recurrence, overall survival and sensitivity to adjuvant chemotherapy in early breast cancer [ 42 , 43 ]. In 2007, FDA approved a risk signature which was developed based on analysis of the expression data of 78 young patients with ER+ and LN- breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Integration RNA bulk and single cell RNA sequencing to explore the change of glycolysis-related immune microenvironment and construct prognostic signature in head and neck squamous cell carcinoma

Nie,

Cao,

Yang

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

“…Integrative analyses provide a more comprehensive view of the molecular alterations underlying colorectal cancer, aiding in the identification of novel biomarkers with potential clinical relevance. The identification and validation of such biomarkers are essential steps toward developing targeted therapies and improving patient outcomes in colorectal cancer. , …”

Section: Molecular Profiling Of Colorectal Cancermentioning

confidence: 99%

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.

show abstract

Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management

Cited by 19 publications

References 97 publications

What's new in thoracic oncology

What's new in thoracic oncology

Integration RNA bulk and single cell RNA sequencing to explore the change of glycolysis-related immune microenvironment and construct prognostic signature in head and neck squamous cell carcinoma

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Contact Info

Product

Resources

About